Together-We-Cure™
Together We Cure™ is a worldwide initiative partnering with those patients with acute myeloid leukemia (AML) who want to better understand their cancer, and take a more active role in their treatment.
Together We Cure™ is the first initiative that provides a global portal promoting and providing access to comprehensive molecular testing of each patient’s cancer in order to accelerate our knowledge and progress towards finding a cure.
Personalized molecular profiling of AML and sharing this information with other professionals in a HIPAA-compliant, anonymized manner will provide physicians and patients the information necessary to rapidly identify drugs and clinical trials that target the individual’s cancer.
Understanding heterogeneous cancers like AML will more rapidly identify and target cancer-specific mutations, which will accelerate drug discovery and drug approval by pharmaceutical companies and clinical trial sites. This approach will accelerate our understanding of AML, lead to better cooperation and dynamic, data-based management of treatment, which will result in better outcomes for patients with AML.
There are 12,000 to 14,000 new cases of AML diagnosed in the United States each year and less than 50,000 new cases in developed countries worldwide. The Together We Cure™ initiative promotes the generation of personalized molecular profiles for each patient and facilitates sharing of these anonymized test results between physicians, patients and cancer treatment centers.
Our goal is to support patients, help educate their physicians, and provide information that will assist clinical scientists to more rapidly identify treatments that work and to accelerate the adoption of new efficacious treatments and drug approval.
The initiative’s mission is to:
- Identify patient- and cancer-specific genetic variations
- Identify how differences in molecular profiles affect treatment outcomes
- Assist patients and physicians in finding the latest peer-reviewed, credible studies and literature on their specific type of AML
- Assist patients and physicians in finding the best clinical trials and treatments targeting their type of AML
- Assist pharmaceutical companies and clinical investigators in identifying drugs targeting AML-specific mutations
